BIOLINERX
Facebook
|
Twitter
|
Linkedin
| Careers | Contact Us
search

SEC Filings
Form 20-F
BIOLINERX LTD. filed this Form 20-F on 03/28/2019
Document Outline
Entire Document (6681.2 KB)
Subdocument 1 - 20-F - 20-F
Page 1 - UNITED STATES
Page 2 - N/A
Page 3 - TABLE OF CONTENTS
Page 4 - INTRODUCTION
Page 5 - PART I
Page 6 - N/A
Page 7 - B. Capitalization and Indebtedness
Page 8 - We may be unable to make payments due under our secured loan agreement.
Page 9 - Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of ea
Page 10 - We generally rely on third parties to conduct our preclinical studies and clinical trials and to pro
Page 11 - We depend on our ability to identify and in-license technologies and therapeutic candidates.
Page 12 - If we do not meet the requirements under our agreement with the Agalimmune selling shareholders, we
Page 13 - If our competitors develop and market products that are more effective, safer or less expensive than
Page 14 - Our business could suffer if we are unable to attract and retain key employees.
Page 15 - Risks Related to Our Industry
Page 16 - If third-party payors do not adequately reimburse customers for any of our therapeutic candidates th
Page 17 - Our business has a substantial risk of clinical trial and product liability claims. If we are unable
Page 18 - Risks Related to Intellectual Property
Page 19 - Patent protection for our products is important and uncertain.
Page 20 - Legal proceedings or third-party claims of intellectual property infringement may require us to spen
Page 21 - Risks Related to our Ordinary Shares and ADSs
Page 22 - We have received a deficiency letter from Nasdaq regarding the current bid price of the ADSs; there
Page 23 - Future sales of our ordinary shares or ADSs could reduce the market price of our ordinary shares and
Page 24 - As a foreign private issuer, we are permitted to follow certain home country corporate governance pr
Page 25 - Due to a significant portion of our expenses and revenues being denominated in non-dollar currencies
Page 26 - Provisions of Israeli law may delay, prevent or otherwise impede a merger with, or an acquisition of
Page 27 - It may be difficult to enforce a U.S. judgment against us and our officers and directors named in th
Page 28 - Therapeutic Candidates
Page 29 - AML
Page 30 - Other matters
Page 31 - Our Product Pipeline
Page 32 - Stem cell mobilization
Page 33 - Clinical Trials.
Page 34 - AML
Page 35 - N/A
Page 36 - Stem cell mobilization
Page 37 - AGI-134
Page 38 - Commercialized Product
Page 39 - Development and Commercialization Arrangement.
Page 40 - Collaboration and Out-Licensing Agreements
Page 41 - Other Out-licensing/Collaboration Agreements
Page 42 - BL-8040
Page 43 - AGI-134
Page 44 - BL-5010
Page 45 - Trade Secrets
Page 46 - Contract Research Organizations
Page 47 - AGI-134
Page 48 - Environmental Matters
Page 49 - United States
Page 50 - Clinical Trials
Page 51 - N/A
Page 52 - Post-Marketing Requirements
Page 53 - FDA Approval or Clearance of Medical Devices
Page 54 - European Economic Area
Page 55 - Centralized Procedure
Page 56 - National Procedure
Page 57 - B. Abridged Applications.
Page 58 - C. Mixed Marketing Authorization Applications
Page 59 - report on the first five years of implementation of the Pediatric Regulation
Page 60 - Israel
Page 61 - N/A
Page 62 - Israel Ministry of Health
Page 63 - ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS
Page 64 - N/A
Page 65 - Sales and Marketing Expenses
Page 66 - General and Administrative Expenses
Page 67 - Accrued Expenses
Page 68 - Stock-based Compensation
Page 69 - Comparison of the Year Ended December 31, 2018 to the Year Ended December 31, 2017
Page 70 - General and administrative expenses
Page 71 - N/A
Page 72 - C. Research and Development, Patents and Licenses
Page 73 - ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
Page 74 - Ella Sorani, Ph.D.,
Page 75 - BJ Bormann, Ph.D.,
Page 76 - B. Compensation
Page 77 - C. Board Practices
Page 78 - Chairman of the Board.
Page 79 - N/A
Page 80 - N/A
Page 81 - Audit Committee
Page 82 - N/A
Page 83 - Compensation Committee
Page 84 - N/A
Page 85 - N/A
Page 86 - Nominating Committee
Page 87 - Approval of Related Party Transactions under Israeli Law
Page 88 - N/A
Page 89 - Disclosure of personal interests of a controlling shareholder and approval of transactions
Page 90 - Duties of shareholders
Page 91 - N/A
Page 92 - D. Employees
Page 93 - E. Share Ownership
Page 94 - Equity Compensation Plan
Page 95 - ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
Page 96 - Indemnification Agreements
Page 97 - ITEM 9. THE OFFER AND LISTING
Page 98 - Dividends
Page 99 - Quorum
Page 100 - N/A
Page 101 - Access to Corporate Records
Page 102 - Merger
Page 103 - Combination Study Agreement with Genentech
Page 104 - Taxation of Israeli Individual Shareholders on Receipt of Dividends.
Page 105 - Taxation of Capital Gains
Page 106 - U.S. Federal Income Tax Considerations
Page 107 - Sale, Exchange or Other Disposition of Ordinary Shares and ADSs.
Page 108 - Passive Foreign Investment Company
Page 109 - Mark-to-Market Election
Page 110 - The U.S. federal income tax rules relating to PFICs are complex. U.S. Investors are urged to consult
Page 111 - Backup Withholding Tax and Information Reporting Requirements
Page 112 - I. Subsidiary Information
Page 113 - Description of the ADSs
Page 114 - Liability of Holders for Taxes, Duties or Other Charges
Page 115 - Internal Control Integrated Framework
Page 116 - ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES
Page 117 - N/A
Page 118 - ITEM 16H. MINE SAFETY DISCLOSURE
Page 119 - ITEM 19. EXHIBITS
Page 120 - N/A
Page 121 - N/A
Page 122 - SIGNATURES
Page 123 - REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Page 124 - Definition and Limitations of Internal Control over Financial Reporting
Page 125 - BioLineRx Ltd.
Page 126 - BioLineRx Ltd.
Page 127 - BioLineRx Ltd.
Page 128 - BioLineRx Ltd.
Page 129 - BioLineRx Ltd.
Page 130 - BioLineRx Ltd.
Page 131 - BioLineRx Ltd.
Page 132 - BioLineRx Ltd.
Page 133 - BioLineRx Ltd.
Page 134 - BioLineRx Ltd.
Page 135 - BioLineRx Ltd.
Page 136 - BioLineRx Ltd.
Page 137 - BioLineRx Ltd.
Page 138 - BioLineRx Ltd.
Page 139 - BioLineRx Ltd.
Page 140 - BioLineRx Ltd.
Page 141 - BioLineRx Ltd.
Page 142 - BioLineRx Ltd.
Page 143 - BioLineRx Ltd.
Page 144 - BioLineRx Ltd.
Page 145 - BioLineRx Ltd.
Page 146 - BioLineRx Ltd.
Page 147 - BioLineRx Ltd.
Page 148 - BioLineRx Ltd.
Page 149 - BioLineRx Ltd.
Page 150 - BioLineRx Ltd.
Page 151 - BioLineRx Ltd.
Page 152 - BioLineRx Ltd.
Page 153 - BioLineRx Ltd.
Page 154 - BioLineRx Ltd.
Page 155 - BioLineRx Ltd.
Page 156 - BioLineRx Ltd.
Page 157 - BioLineRx Ltd.
Page 158 - BioLineRx Ltd.
Page 159 - BioLineRx Ltd.
Page 160 - BioLineRx Ltd.
Page 161 - BioLineRx Ltd.
Page 162 - BioLineRx Ltd.
Page 163 - BioLineRx Ltd.
Page 164 - BioLineRx Ltd.
Page 165 - BioLineRx Ltd.
Subdocument 2 - EX-4.5 - EXHIBIT 4.5
Page 1 - Exhibi 4.5
Page 2 - IN WITNESS WHEREOF,
Subdocument 3 - EX-4.41 - EXHIBIT 4.41
Page 1 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Page 2 - [Remainder of page intentionally left blank.]
Page 3 - BioLineRx Ltd.
Page 4 - N/A
Page 5 - EXHIBIT
Page 6 - EXHIBIT
Subdocument 4 - EX-4.47 - EXHIBIT 4.47
Page 1 - Exhibit 4.47
Page 2 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Page 3 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Page 4 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Page 5 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Page 6 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Page 7 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Page 8 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Page 9 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Page 10 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Page 11 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Page 12 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Page 13 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Page 14 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Page 15 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Page 16 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Page 17 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Page 18 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Page 19 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Page 20 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Page 21 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Page 22 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Page 23 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Page 24 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Page 25 - [*] Represents material that has been omitted and will be filed separately with the Securities and E
Subdocument 5 - EX-4.49 - EXHIBIT 4.49
Page 1 - Exhibi 4.49
Page 2 - N/A
Page 3 - N/A
Subdocument 6 - EX-4.50 - EXHIBIT 4.50
Page 1 - AMENDMENT NO. 1 TO LICENSE AGREEMENT
Page 2 - IN WITNESS WHEREOF,
Subdocument 7 - EX-12.1 - EXHIBIT 12.1
Page 1 - N/A
Subdocument 8 - EX-12.2 - EXHIBIT 12.2
Page 1 - N/A
Subdocument 9 - EX-13.1 - EXHIBIT 13.1
Page 1 - N/A
Subdocument 10 - EX-13.2 - EXHIBIT 13.2
Page 1 - N/A
Subdocument 11 - EX-15.5 - EXHIBIT 15.5
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE (What's this?)
XBRL Viewer


Interview with Philip Serlin, CEO
December 2016